Dr. John Fleetham chats with Dr. Kelly Dooley about her paper, "Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-containing Regimens for Drug-sensitive TB: 12-Week Results."